The Supplement That Spent 30 Years Being Right Too Early
Creatine has a strange story. And if you're in the business of building health claims, it's one worth sitting with for a moment.
For most of its commercial life, creatine was a gym supplement. A bodybuilder's tool. Something you'd find in a tub next to protein powder, bought by people whose primary metric was how much they could bench press. The evidence for it in that context was, and still is, overwhelming — add lean muscle mass, improve high-intensity performance, recover faster. Decades of well-controlled trials, consistent results, a clear mechanism. By any scientific standard, the case was settled.
And yet, for most of that time, creatine was invisible to the broader wellness market. No mainstream supplement brand was leading with it. No GP was recommending it to their fifty-something patients. No one was writing think-pieces about its potential. It was just... a gym thing.
Then, in roughly the space of eighteen months, everything changed.
What actually happened
Andrew Huberman started talking about creatine and cognitive performance on his podcast. Joe Rogan followed. Mel Robbins. Suddenly the ingredient that had spent decades quietly accumulating one of the strongest evidence bases in sports nutrition was being discovered — not by athletes, but by everyone else.
"The global creatine supplements market hit $1.1 billion in 2024 and is projected to reach $4.2 billion by 2030, growing at over 25% annually (Grand View Research) — with a significant portion of that growth driven not by gym performance but by brain health and healthy aging."
None of this science is brand new. The mechanism — creatine supporting energy metabolism in the brain the same way it does in muscle tissue — has been understood for years. What changed wasn't the evidence. What changed was who was paying attention to it.
That distinction matters more than most brands realise.
The evidence was always there
Here's the thing that should give any brand strategist pause: creatine's emerging applications in brain health and women's health aren't speculative. The science has been building quietly and seriously for years, it just wasn't commercially visible.
Females have been reported to have lower levels of creatine in the brain, particularly the frontal lobe, which controls mood, cognition, memory, and emotion — and as a result, supplementation may be even more effective for females for supporting a pro-energetic environment in the brain. PubMed Central Research has been examining creatine's role in mood, depression, perimenopause, and cognitive ageing for well over a decade. Researchers at SupplySide Global 2025 referenced two Alzheimer's trials published that year using higher creatine doses over eight weeks that showed significant improvements in cognitive markers. Capros
This wasn't a sudden scientific breakthrough. It was a slow accumulation of evidence that finally reached critical mass in the public conversation. The science crossed a threshold — not a regulatory one, not a clinical one, but a cultural one.
And most brands were completely unprepared for it.
Being right too early looks exactly like being wrong
This is the uncomfortable truth about evidence timing: there is a window between when the science is genuinely there and when the market — and regulatory frameworks — are ready to act on it. In that window, being scientifically correct offers almost no commercial advantage.
A brand that had been quietly building creatine's brain health positioning five years ago would have been largely ignored. The consumer wasn't listening. The podcasters hadn't picked it up. The category wasn't visible. You can be sitting on solid, peer-reviewed evidence and still go nowhere, because evidence doesn't create its own audience.
But there's a second, equally important problem on the other side of the window: brands that rush in the moment a trend reaches cultural visibility, without having done the evidence work first. They borrow the excitement of a category before understanding what claims they can actually defend — and they end up in front of regulators or plaintiff attorneys who are not interested in the podcast moment that inspired the label copy.
The creatine story illustrates both failure modes with uncomfortable clarity.
The commercial lesson
What creatine actually teaches is that evidence strategy and timing strategy need to run together — and that the brands who get this right are the ones who are reading the science before the podcasters are, not after.
The ingredients with the most commercial potential right now are rarely the ones that have already made it onto the wellness influencer circuit. By the time a claim is being made enthusiastically by a hundred brands at once, the easy gains have been taken, the regulatory scrutiny is rising, and differentiation is harder. The real opportunity lives one step earlier: in ingredients and mechanisms where the evidence is genuinely building, the consumer narrative hasn't crystallised yet, and there's still time to build a defensible, specific claim before the category gets crowded.
Current research on creatine and brain health suggests the existing body of evidence is still small, incohesive, and that critical knowledge gaps remain ScienceDirect — which is precisely the kind of moment that rewards brands who engage seriously with the science rather than simply borrowing the headline. The broad cultural claim ("creatine is good for your brain") is already available to everyone. The specific, defensible, population-targeted claim — backed by evidence that maps directly to your product, dose, and consumer — is still there to be built.
That's true of creatine right now. It was true of omega-3s twenty years ago. It will be true of whatever ingredient is having its cultural moment in 2028.
What this means in practice
The brands that consistently get claims right aren't the ones with the best marketing instincts. They're the ones who treat evidence as a strategic asset to be built over time, not a box to be ticked just before launch.
That means monitoring the science before it becomes a trend. It means understanding which of your ingredient's mechanisms have robust human evidence behind them and which are still in the mechanistic-or-rodent-study phase. It means knowing the difference between a claim you can make today and one that needs another two years of research before it's defensible — and making a deliberate decision about which category you're playing in.
Creatine spent thirty years being right too early. The brands who understand that story, and learn from it, won't make the same mistake — in either direction.
At Parallaxis, evidence strategy is something we build before the brief — not after it. If you're navigating an ingredient or category where the science is moving faster than the claim landscape, let's talk.